Promising activity of nelfinavir-…

Treatment of proteasome inhibitor (PI)-refractory multiple myeloma (MM) is challenging, with response rates of only 15% to 35% being achieved with next-generation drugs such as pomalidomide, carfilzomib, and daratumumab, alone…

Categories: